The FDA's approval of Epidiolex, to treat seizures associated with 2 rare forms of epilepsy, represents the first approval for a drug containing a purified drug substance from marijuana.
The FDA recently approved Epidiolex (cannabidiol [CBD]) oral solution for treating seizures associated with 2 rare forms of epilepsy—Lennox-Gastaut syndrome and Dravet syndrome. The approval is for patients 2 years of age or older and marks the first FDA-approved drug that contains a purified drug substance from marijuana.
“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development,” FDA Commissioner Scott Gottlieb, MD, said in a statement. “Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients.”
CBD, a chemical component of the Cannabis sativa plant, does not cause intoxication or euphoria that tetrahydrocannabinol (THC) does. THC is the primary psychoactive component of marijuana, not CBD.
The approval of Epidolex marks the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Dravet syndrome is a rare genetic condition that appears with frequent fever-related seizures (febrile seizures) during the first year of life. Over time, additional types of seizures, such as myoclonic seizures (involuntary muscle spasms) will often occur. Also, there is also a chance that status epilepticus—a potentially life-threatening state of continual seizure activity that requires medical care—may occur with Dravet syndrome.
“The difficult-to-control seizures that patients with Dravet syndrome and Lennox-Gastaut syndrome experience have a profound impact on these patients’ quality of life,” said Billy Dunn, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “In addition to another important treatment option for Lennox-Gastaut patients, this first-ever approval of a drug specifically for Dravet patients will provide a significant and needed improvement in the therapeutic approach to caring for people with this condition.”
The other rare form of epilepsy, Lennox Gastaut syndrome begins in childhood involves multiple types of seizures, starting between ages 3 and 5. The majority of children with this syndrome develop learning problems, intellectual disability, and delayed development of motor skills.
The efficacy of the drug was evaluated in 3 randomized clinical trials involving 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex when taken with other medication was found to be effective in decreasing the frequency of seizures.
The most common side effects included sleepiness, sedation and lethargy, elevated liver enzymes, decreased appetite, diarrhea, rash, fatigue, malaise and weakness, insomnia, sleep disorder, and infections.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More